• Jashvant Poeran, Genewoo Hong, and Stavros G Memtsoudis.
• Institute for Healthcare Delivery Science, Departments of Orthopaedics / Population Health Science & Policy / Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
• Reg Anesth Pain Med. 2023 Oct 1; 48 (10): 526529526-529.

AbstractLiposomal bupivacaine has been the topic of intense academic debate over the past years culminating in an industry-initiated libel lawsuit against the American Society of Anesthesiologists and various other defendants. In this Daring Discourse, we first aim to provide a general overview of main themes in the ongoing controversy: (1) between-study heterogeneity, (2) the high number of negative high-quality reviews and meta-analyses, (3) publication bias in the context of an active role of industry and (4) difference between statistical and clinical significance. We then discuss the contents of the lawsuit, its potential implications and what the recent resolution of this lawsuit means for the future of research and the academic discourse on liposomal bupivacaine.© American Society of Regional Anesthesia & Pain Medicine 2023. No commercial re-use. See rights and permissions. Published by BMJ.

12 keywords...

hide…